Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): protocol for a multicountry novel artificial intelligence-based imaging device.
Thomas A Odeny, Harriet Fridah Adhiambo, Dorothy Mangale...
https://pubmed.ncbi.nlm.nih.gov/42282156/Actively Recruiting
Led by Washington University School of Medicine · Updated on 2026-09-21
180
Participants Needed
2
Research Sites
52 weeks
Total Duration
Researchers are evaluating the precision and usability of SkinScan3D, a handheld device that uses liquid lens technology and artificial intelligence, for measuring Kaposi Sarcoma KS skin lesions. The study aims to compare this devices measurements against the current manual ruler-based method to assess reproducibility and accuracy. This trial involves patients with KS undergoing treatment, aiming to improve lesion measurement techniques in real-world care settings. Participants will have three KS skin lesions measured both manually and with SkinScan3D. During the first three months, providers will use the standard manual ruler method, after which they will switch to the SkinScan3D device for measurements. The study evaluates if SkinScan3D is usable, acceptable, appropriate, and feasible in routine clinical care, with the device automatically calculating lesion areas from multiple 3D snapshots. Throughout the study, measurements will be taken repeatedly over approximately six months to assess device usability and measurement accuracy. Participants must have confirmed KS with at least three skin lesions and be receiving treatment. Researchers will monitor lesion size measurement consistency and device performance while participants continue their usual care. The total study duration extends through November 2029, with primary outcomes assessed within the first six months.
CONDITIONS
Precision Imaging to Evaluate Kaposi Sarcoma
T
Thomas Odeny, MBChB, MPH, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Washington University School of Medicine
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 3 months
For the first three months, providers measure Kaposi Sarcoma skin lesions using the standard manual ruler method.
Regular visits as per routine care
Duration - Up to 6 months
After three months, providers switch to using the SkinScan3D device to measure skin lesions automatically from 3D images.
Regular visits as per routine care
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Thomas A Odeny, Harriet Fridah Adhiambo, Dorothy Mangale...
https://pubmed.ncbi.nlm.nih.gov/42282156/Washington University School of Medicine
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor